推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733，021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

METHODS OF TREATING MYELODYSPLASTIC SYNDROMES USING LENALIDOMIDE

JB Zeldis - US Patent 20,110,172,273, 2011 - freepatentsonline.com
... variety of dermatological conditions, ulcerative colitis, Crohn's disease, Bechets's syndrome,
systemic lupus ... The term “myelodysplastic syndromes” or “MDS” unless otherwise noted includes:
refractory ... not limited to: tablets; caplets; capsules, such as soft elastic gelatin capsules ...
Cached

… for Myelodysplastic Syndromes in Older Patients in the Context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic …

[HTML] from 171.66.121.246SA Giralt, M Horowitz, D Weisdorf… - Journal of Clinical …, 2011 - 171.66.121.246
... Previous Section. REFERENCES. ↵: Dansey R. (2000) Myelodysplasia. Curr Opin Oncol
12:13–21. ... (2002) Randomized controlled trial of azacitidine in patients with myelodysplastic
syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429–2440. ...
Related articles - All 6 versions

[PDF] Reduced ribosomal protein gene dosage and p53 activation in low risk myelodysplastic syndrome.

[PDF] from hematologylibrary.orgKA McGowan, WW Pang, R Bhardwaj… - …, 2011 - bloodjournal.hematologylibrary.org
... Running title: Ribosomal protein mutations in myelodysplasia ... Reduced gene dosage of ribosomal
protein subunits has been implicated in 5q- myelodysplastic syndrome and Diamond Blackfan
anemia, but the cellular and pathophysiologic defects associated with these ...
View as HTML

Quantitative assessment of myeloid nuclear differentiation antigen distinguishes myelodysplastic syndrome from normal bone marrow

SA McClintock-Treep, RC Briggs… - American journal of …, 2011 - ajcp.ascpjournals.org
Quantitative Assessment of Myeloid Nuclear Differentiation Antigen Distinguishes
Myelodysplastic Syndrome From Normal Bone Marrow. ...
Cited by 2 - Related articles - All 4 versions

Methods of using 4-(amino)-2-(2, 6-dioxo (3-piperidly))-isoindoline-3-dione for the treatment of myelodysplastic syndromes

JB Zeldis - US Patent 7,863,297, 2011 - Google Patents
... Rajapaksa et al., 1996, Altered oncoprotein expression and apoptosis in myelodysplastic
syndrome marrow cells ... ing stromal and hematopoietic cells in 50 patients with myelodysplastic
syndromes," Blood ... r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS)," Br ...
Related articles - All 4 versions

联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

© 2010-2024 中国: LetPub上海分公司    网站备案号：沪ICP备10217908号-1    沪公网安备号：31010402006960

增值电信业务经营许可证：沪B2-20211595

礼翰商务信息咨询（上海）有限公司      办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室

United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451